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ABSTRACT
Flaviviruses are positive-sense, single-stranded RNA viruses responsible for millions of human infections annually. The enve-
lope (E) protein of flaviviruses comprises three structural domains, of which domain III (EIII) represents a discrete subunit. The
EIII gene sequence typically encodes epitopes recognized by virus-specific, potently neutralizing antibodies, and EIII is believed
to play a major role in receptor binding. In order to assess potential interactions between EIII and the remainder of the E protein
and to assess the effects of EIII sequence substitutions on the antigenicity, growth, and virulence of a representative flavivirus,
chimeric viruses were generated using theWest Nile virus (WNV) infectious clone, into which EIIIs from nine flaviviruses with
various levels of genetic diversity fromWNVwere substituted. Of the constructs tested, chimeras containing EIIIs from Kou-
tango virus (KOUV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV), and Bagaza virus (BAGV) were suc-
cessfully recovered. Characterization of the chimeras in vitro and in vivo revealed differences in growth and virulence between
the viruses, with in vivo pathogenesis often not being correlated with in vitro growth. Taken together, the data demonstrate that
substitutions of EIII can allow the generation of viable chimeric viruses with significantly altered antigenicity and virulence.
IMPORTANCE
The envelope (E) glycoprotein is the major protein present on the surface of flavivirus virions and is responsible for mediating
virus binding and entry into target cells. Several viableWest Nile virus (WNV) variants with chimeric E proteins in which the
putative receptor-binding domain (EIII) sequences of other mosquito-borne flaviviruses were substituted in place of theWNV
EIII were recovered, although the substitution of several more divergent EIII sequences was not tolerated. The differences in vir-
ulence and tissue tropism observed with the chimeric viruses indicate a significant role for this sequence in determining the
pathogenesis of the virus within the mammalian host. Our studies demonstrate that these chimeras are viable and suggest that
such recombinant viruses may be useful for investigation of domain-specific antibody responses and the more extensive defini-
tion of the contributions of EIII to the tropism and pathogenesis ofWNV or other flaviviruses.
The Flavivirus genus is a large genus of viruses with positive-sense, single-stranded RNA genomes responsible for signifi-
cant globalmorbidity andmortality (1). The fact that themajority
are vector borne, being carried by either ticks or mosquitoes, al-
lows them to have a wide geographical distribution and to be
readily transmitted to humans. The clinical manifestations of fla-
vivirus infections in humans vary considerably, with many caus-
ing nonspecific febrile illnesses that may progress to more severe
syndromes, including hemorrhagic fever or encephalitis (1).
The surface of mature flavivirus virions is primarily comprised
of 180 copies of the envelope (E) glycoprotein (2). As a result, the
E protein is involved in the major steps of virus entry into suscep-
tible cells, including themediation of receptor binding and fusion
between the viral envelope and host endosomal membranes, al-
lowing the release of the viral genomic RNA into the cell cyto-
plasm for replication (3–6). These roles require considerable re-
arrangement of the E proteins on the surface of themature virion,
with important intra- and intermolecular interactions occurring
at each stage (3, 7). Structurally, Emay be divided into threemajor
domains: EI, which in many West Nile virus (WNV) strains in-
cludes the single glycosylation motif; EII, which contains the fu-
sion loop conserved among flaviviruses; and EIII, the putative
receptor-binding domain (8). Although all three domains of the E
protein appear to contribute to interactions with target cell li-
gands in different experimental systems, data that support a sig-
nificant role for EIII in receptor binding come from investigations
into competition between recombinant EIII molecules and infec-
tious virions for adsorption to cell surfaces (9–11), immunologi-
cal studies using neutralizing monoclonal antibodies (MAbs) tar-
geting EIII (12), studies in which mutant viruses containing
particular amino acid substitutions in EIII were generated (13–
19), and investigations with dengue virus (DENV) E fusion pro-
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teins (6). Studies of EIII protein subunits derived from different
mosquito- and tick-borne flaviviruses have identified virus-spe-
cific differences in antigenicity, surface biochemistry, and
structure, which further support a role for EIII as a key deter-
minant of ligand binding and cell tropism for individual flavi-
virus types (20–28).
Construction of chimeric flaviviruses, whereby segments of the
genome of one virus are substituted into the genome of a different
flavivirus, has been used to investigate the roles of individual viral
proteins in virulence or other phenotypes or to develop candidate
vaccines and diagnostic reagents. In flaviviruses with chimeric
structural proteins described previously, the coding sequences for
complete structural proteins, usually prM and E, from a donor
virus were substituted into a backbone virus (29–56). These chi-
meric viruses have antigenic characteristics that are determined by
the donor structural proteins, and characterization of several has
also identified significant shifts in in vitro growth and/or in vivo
virulence phenotypes, consistentwith the importance of the struc-
tural proteins and, in particular, E in those phenotypes. For exam-
ple, the substitution of prM-E from tick-borne encephalitis virus
(TBEV) into DENV serotype 4 (DENV-4) significantly affected
the behavior of the virus both in vitro and in vivo, with growth in
LLC-MK2 cells resulting in higher peak titers of the chimeric virus
than theDENV-4 control andwith intracerebral (i.c.) administra-
tion resulting in increased neurovirulence compared to the level of
neurovirulence achieved with the equivalent dose of DENV-4
(30). Studies with similar chimeras comprised of prM-E from
TBEV substituted into Omsk hemorrhagic fever virus (OHFV) as
the backbone virus showed significantly earlier neuroinvasion by
the chimeric virus than by the OHFV control, further indicating
that the structural proteins can affect the behavior of the virus
(52).
To date, few studies have attempted to generate chimeric pro-
teins (i.e., proteins containing domains/regions derived from two
or more different flaviviruses) and incorporate them into a viable
virus. Given the discrete nature of EIII within the flavivirus E
protein, as well as its role in receptor binding and as a target for
virus-specific neutralizing antibodies, we hypothesized that sub-
stitution of EIII sequences between some flaviviruses would yield
viable viruses but would likely be associated with significant
changes in the growth, virulence, and/or antigenicity of the result-
ing chimeras. Therefore, the aims of this study were (i) to deter-
mine whether viable chimeras could be generated via the substi-
tution of the EIII protein domain alone (i.e., chimerization of the
E protein) and (ii) to assess the effects of EIII substitutions on the
in vitro growth and in vivo pathogenesis of these chimeras. WNV,
an encephalitic, mosquito-borne flavivirus, was used as the back-
bone virus for these initial investigations due to the availability of
a well-characterized infectious clone system (57) and small-ani-
mal neuroinvasive disease models.
MATERIALS AND METHODS
WNVNY99 infectious clone and EIII donor viruses. For the generation
of chimeric viruses, a previously described WNV infectious clone system
was employed (57, 58). Briefly, the infectious clone consisted of two plas-
mids: pWN-AB, which contained the 5= untranslated region (UTR) and
the structural protein coding region, and pWN-CG, which contained the
nonstructural protein coding region and the 3= UTR. For virus recovery,
the two plasmids were digested with XbaI and NgoMIV (New England
BioLabs, Ipswich, MA) and ligated together after purification. The ligated
full-length plasmid was linearized with XbaI, and full-length genome-
equivalent RNA was produced by in vitro transcription from a T7 pro-
moter upstream of the coding sequence using an Ampliscribe T7-Flash in
vitro transcription kit (Epicentre Biotechnologies, Madison, WI). Virus
recovery was carried out by electroporating the in vitro-transcribed RNA
into Vero cells (ATCC, Manassas, VA) using an Invitrogen Neon trans-
fection system (Life Technologies, Waltham, MA).
Four unique restriction sites (SalI at nucleotides [nt] 1829 to 1834, PstI
at nt 1859 to 1864, StuI at nt 2183 to 2188, and BamHI at nt 2251 to 2256)
were engineered into the pWN-AB plasmid by site-directed mutagenesis
using QuikChange XL and Multi kits (Agilent Technologies, Santa Clara,
CA). The locations of the sites were chosen on the basis of the strongly
conserved amino acid sequences in these regions among many of the
flaviviruses. Three of the four mutations were silent at the amino acid
level; however, the mutation at the SalI site resulted in a conservative
V290L amino acid substitution in E. This substitution has been identified
in natural, pathogenic isolates of WNV, including the T2 strain from
Turkey (59). Nine EIII donor viruses with increasing levels of genetic
diversity from WNV were used (Table 1). cDNA for all but one of the
viruses was derived from isolated viral RNA obtained from the World
Reference Center for Emerging Viruses and Arboviruses (WRCEVA) at
the University of Texas Medical Branch (UTMB). The Zika virus (ZIKV)
EIII sequence was amplified from a synthetic construct purchased from
BioBasic Inc. (Markham,ON)on the basis of the published sequencewith
GenBank accession number NC_012532.
Construction of chimeric plasmids. Viral RNA was extracted from
culture supernatant samples of each donor virus using the TRIzol reagent
(Thermo Fisher Scientific, Waltham, MA), with RNA purification being
performed using a Zymo Direct-Zol RNA purification kit (Zymo Re-
search Corp., Irvine, CA). Reverse transcription to generate viral cDNA
was performed using New England BioLabs avian myeloblastosis virus
reverse transcriptase (New England BioLabs, Ipswich, MA). EIII inserts
were amplified from cDNA generated from viral genomic RNA or a syn-
thetic plasmid using the Roche High Fidelity PCR master mix (Roche,
Indianapolis, IN). The PCR products were separated by agarose gel elec-
trophoresis and purified using a Qiagen QIAquick gel extraction kit (Qia-
gen, Germantown, MD). Both the purified PCR products and backbone
plasmids were digested with the appropriate restriction enzyme pairs
(New England BioLabs, Ipswich, MA).
For seven of the EIII donor viruses, four chimera versions, denoted
chimeric constructs A, B, C, and D, were generated using each combina-
tion of the up- and downstream restriction sites (Fig. 1A). For yellow fever
virus (YFV) and deer tick virus (DTV), only the A- and B-form chimeric
plasmids were generated. On the basis of the location of the restriction
sites, the B form (PstI-StuI) had the smallest insert, consisting solely of
EIII, whereas the A form (SalI-BamHI) had the largest substitution, con-
taining part of EI upstream of the EI/EIII linker region and the first stem-
helix region downstream. The C and D forms (with SalI-StuI and PstI-
BamHI, respectively) had the additional upstream and downstream
sequences, respectively. For the B forms, an infectious clone pWN-AB
TABLE 1 EIII donor viruses used for chimerization
Donor virusa Strain Source
Koutango virus (KOUV) Dak Ar D 5443 Viral RNA
Japanese encephalitis virus (JEV) Nakayama Viral RNA
St. Louis encephalitis virus (SLEV) Parton Viral RNA
Bagaza virus (BAGV) DakAr B209 Viral RNA
Zika virus (ZIKV) MR 766 Synthetic construct
Iguape virus (IGUV) SPAn 71686 Viral RNA
Dengue 2 virus (DENV-2) New Guinea C Viral RNA
Yellow fever virus (YFV) Asibi Viral RNA
Powassan virus (POWV)/deer tick
virus (DTV)
DTV IPS-001 Viral RNA
a EIII donor viruses were chosen on the basis of their genetic divergence fromWNV
NY99. Where possible, prototype donor viruses were used.
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Koutango Virus
Japanese Encephalitis Virus
St Louis Encephalitis Virus
Bagaza Virus
Dengue 2 Virus
Powassan/Deer Tick Virus
West Nile Virus
Iguape Virus
Zika Virus
Koutango Virus
Japanese Encephalitis Virus
St Louis Encephalitis Virus
Bagaza Virus
Dengue 2 Virus
Powassan/Deer Tick Virus
West Nile Virus
Iguape Virus
Zika Virus
* First two amino acids “LQ” in B- and D-forms
*
*
*
*
*
Yellow Fever Virus
Yellow Fever Virus
A-Form (SalI/BamHI)
B-Form (PstI/StuI)
C-Form (SalI/StuI)
D-Form (SalI/BamHI)
A-Form (SalI/BamHI)
B-Form (PstI/StuI)
C-Form (SalI/StuI)
D-Form (SalI/BamHI)
289 300 310 320 330 340 350 359
360 370 380 390 400 410 420 430
SalI PstI
StuI BamHI
B) 
EH2 TM2
EH1 TM1I II I II I III
I II I II I III EH1 TM1
Structural Domains of 
Envelope Glycoprotein (E) 
EH1
EH2
TM1
TM2
EH1
EH2
TM1
TM2
EH1
EH2
TM1
TM2
EH2 TM2
Chimeric Construct A 
(SalI/BamHI)
Chimeric Construct B 
(PstI/StuI)
Chimeric Construct C 
(SalI/StuI)
Chimeric Construct D 
(PstI/BamHI)
Raised regions indicate
sequence from donor virus
I II I II I III
I II I II I III
I II I II I III
A)
FIG 1 Schematic overview of chimera insert sizes and locations and sequence alignment of donor EIII sequences. (A) Donor EIII sequences were cloned into the
WNV infectious clone using four combinations of up- and downstream restriction sites. The four resulting constructs were labeled A, B, C, and D. The A forms
had the largest insertion size, with the donor virus EIII sequence being flanked by the donor virus EI sequence upstream and the first stem-helix structure
downstream. The B forms contained donor virus EIII without the additional sequences, while the C and D forms contained the extra up- and downstream
sequences, respectively. EH, E helical domain; TM, transmembrane domain. (B)Donor virus EIII amino acid sequenceswere aligned to determine the differences
present in the chimeric viruses. Amino acid position numbers correspond to those of theWNVNY99E sequence. Alignmentswere performedusing theGeneious
(v9.0.2) program (Biomatters, Auckland, New Zealand).
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plasmid containing just PstI and StuI sites was used, thereby allowing
chimeras without the SalI-associated V290L substitution to be generated.
The digested plasmids and inserts were gel purified and ligated over-
night at 4°C using T4 DNA ligase (New England BioLabs, Ipswich, MA).
The ligated plasmids were sequenced to confirm their identities and were
transformed into Escherichia coliDH5, from which glycerol stocks were
generated for storage. Chimeric viruses were recovered following ligation
of full-length genomic cDNA, in vitro transcription, and electroporation
of the RNA into Vero cells as described above.
The construction of EIII chimeras using theWNV infectious clonewas
approved by the University of Texas Medical Branch Institutional Bio-
safety Committee. Only EIII sequences derived from viruses of the same
or lower biosafety level (BSL) were used for attempts at chimerization,
and all transfected cell cultures were handled under BSL-3 conditions. All
subsequent experimentation with viable chimeric viruses occurred under
BSL-3/animal BSL-3 (ABSL-3) conditions.
Nucleotide sequencing. Plasmids carrying the chimeric infectious
clones and PCR-amplified viral cDNA generated from TRIzol-extracted
RNA from the cell culture supernatant were submitted to the UTMB
Molecular Genomics core facility for sequence determination using an
Applied Biosystems 3130xl DNA sequencer (Applied Biosystems, Wal-
tham, MA). The whole-genome sequences of recovered and serially pas-
saged chimeric viruses were determined from purified viral RNA samples
at the UTMBNext Generation Sequencing core facility using an Illumina
HiSeq 1500 next generation sequencer (Illumina Inc., San Diego, CA).
Plaque, immunofocus, and TS assays.Virus titration was carried out
in Vero cells grown in minimal essential medium (MEM; Corning, Ma-
nassas, VA) containing 8% fetal calf serum (FCS; HyClone, Logan, UT),
1 penicillin-streptomycin (Corning, Manassas, VA), 1 nonessential
amino acids (Corning, Manassas, VA), and 1 L-glutamine (Life Tech-
nologies, Waltham, MA). Cells were plated in 6-well plates and grown
until they reached approximately 90% confluence. Virus culture superna-
tant samples, serum samples, or homogenized organ tissue samples were
serially 10-fold diluted (typical dilution range, 102 to 107) in MEM
containing 2% FCS. The diluted samples were transferred to the plated
cells, and the viruses were allowed to incubate with the cells for 30 min at
37°C. After the incubation, the cells were overlaid with 4 ml per well of
MEM-agar (1:1 ratio of 2% agar and 2MEM[Quality Biological, Gaith-
ersburg, MD] with 4% FCS and 2 supplements). The plates were incu-
bated for 48 h at 37°C with 5% CO2, after which 2 ml of MEM-agar
containing 2% neutral red (Sigma-Aldrich, St. Louis, MO) was added to
each well. The plates were incubated for a further 24 h before the plaques
were counted. For crystal violet staining and immunostaining, the cells
were fixed on day 3 postinfection with 10% buffered formalin (Fisher
Scientific, Waltham, MA) before the agar plugs were removed. Cells were
stained with crystal violet using a 0.25% crystal violet solution (Sigma-
Aldrich, St. Louis, MO). Immunostaining was carried out by permeabi-
lizing the cells using 70% ethanol per well, followed by incubation
at 20°C for 30 min. The cells were blocked using phosphate-buffered
saline containing 0.5% I-Block blocking reagent (ThermoScientific, Pitts-
burgh, PA). The primary antibody used was an anti-WNV mouse im-
mune ascitic fluid (MIAF; stock number T-35345) obtained from the
WRCEVA. A horseradish peroxidase (HRP)-conjugated anti-mouse im-
munoglobulin secondary antibody (Sigma-Aldrich, St. Louis, MO) was
used with True Blue HRP substrate (KPL, Gaithersburg, MD).
Temperature sensitivity (TS) has previously been used as a marker of
the possible attenuation of virulence of naturally occurring and recombi-
nant WNV variants (60–62), and TS assays were carried out as described
above for the plaque assays. Duplicate plates were prepared for each sam-
ple, and following the first MEM-agar overlay, one of the plates was incu-
bated at 37°C, while the other was incubated at 41°C. The plaque counts
andmorphologies at the two temperatures were compared following 72 h
of total incubation, and a neutral red overlay was used to determine tem-
perature sensitivity.
Virus stability.To compare the relative particle stability of the chime-
ric viruses, 1.2-ml 1:20 dilutions of each virus stock were prepared in
MEM containing 2% FCS, with duplicate samples being placed at 37°C
and 4°C. After thorough vortexing, 150 l of each duplicate sample was
harvested at the 0-h, 12-h, 24-h, 36-h, 48-h, and 72-h time points. The
harvested sampleswere titrated in 12-well plates as described above for the
plaque assays. The virus titers at each time point were determined and
normalized to the values at 0 h to give a value of the percentage of virus
remaining for each sample. The normalized data were plotted using
GraphPad Prism (v6.0g) software (GraphPad, La Jolla, CA) and fitted
with a one-phase decay nonlinear regression to determine particle half-
lives with 95% confidence intervals (CIs).
Growth kinetics. Vero and C6/36 cells were plated in T-25 tissue cul-
ture flasks. Cells in triplicate flasks for each virus were infected with 1,000
PFU virus at a multiplicity of infection (MOI) of 5 104 to allow deter-
mination of minor differences in growth kinetics. The inoculating doses
were confirmed by back-titration. Aliquots of supernatant of 500 l were
removed daily on days 0, 1, 2, 3, 4, and 5 postinfection and were clarified
by centrifugation prior to storage at80°C until titration. The virus titers
in the samples were determined by plaque assay.
Western blotting. Cell lysates were prepared from the Vero cells used
for the growth kinetics analysis on day 5 postinfection. Lysates were pre-
pared using Invitrogen NuPAGE LDS sample buffer (Life Technologies,
Waltham,MA) and were heat inactivated at 95°C for 30 min before being
stored at20°C until use. The nonreduced protein samples were run on
15-well NuPAGENovex 4 to 12%bis-Tris protein gels (Life Technologies,
Waltham, MA) using an XCell SureLock Mini-Cell gel tank (Life Tech-
nologies, Waltham,MA) in which the loading volume was normalized by
the band intensity with the flavivirus EII-reactive 4G2 monoclonal anti-
body (EMD Millipore, Billerica, MA). Proteins were transferred to a ni-
trocellulose membrane (GE Healthcare Life Sciences, Pittsburgh, PA) us-
ing anXCell II blotmodule (Life Technologies,Waltham,MA). Following
transfer, the blots were processed using a WesternBreeze chemilumines-
cent mouse kit (Life Technologies, Waltham, MA) following the manu-
facturer’s instructions. Anti-WNV EIII-specific monoclonal antibody
3A3 (BioReliance Corp., Rockville, MD) and anti-JEV EIII monoclonal
antibody ab81193 (Abcam, Cambridge, MA) were used to determine EIII
antigenic specificity. MIAFs raised against WNV lineage I, WNV lineage
II, Japanese encephalitis virus (JEV) Nakayama, St. Louis encephalitis
virus (SLEV) Parton, and Bagaza virus (BAGV) DakAr B209 were ac-
quired from the WRCEVA collection. Previously described human sera
from WNV-infected patients were also used (63). The deidentified sera
were used under an exemption approved by the UTMB Institutional Re-
view Board. For the human sera, an HRP-conjugated anti-human IgG
(Sigma-Aldrich, St. Louis, MO) was used with the Pierce SuperSignal
West Femto reagent (Thermo Fisher, Waltham, MA). Antibody binding
was detected via exposure of membranes to Amersham Hyperfilm ECL
X-ray films (GE Healthcare Life Sciences, Pittsburgh, PA) that were de-
veloped using a Kodak X-OMAT 2000 X-ray film processor (Kodak,
Rochester, NY).
Neutralization assays. Vero cells were plated in 12-well plates and
grown until they were approximately 90% confluent. Once the cells were
ready, serial 2-fold dilutions of MIAF and serum samples in MEM con-
taining 2% FCS to a total volume of 60 l per well were prepared in
duplicate in 96-well plates. One well in each dilution series contained
MEM–2% FCS only as a negative control. Previously titrated virus stocks
were diluted to a final concentration of 1,000 PFU/ml, and 60 l was
added to each well, giving approximately 60 PFU per well. The virus-
antibody mixtures were incubated at room temperature for an hour to
allow neutralization to occur. After the incubation, 100l of the duplicate
virus-antibody mixtures was added to each well on the 12-well plate, and
each plate also contained duplicate wells with MEM and virus only as a
control. The plates were incubated at room temperature for 30 min, be-
fore 2 ml of MEM-agar overlay was applied to each well. The plates were
then incubated at 37°Cwith 5%CO2 for 48 h, before being fixedwith 10%
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buffered formalin and immunostained as described above. Fifty percent
neutralization titer (NT50) values were determined for each virus-anti-
body combination by identifying the dilutions of antibody that led to a
50% reduction in focus number in thewell compared to the focus number
in the virus-only control wells.
Mouse virulence studies. Three- to 4-week-old female SwissWebster
mice (Harlan, Indianapolis, IN) were used as the animal model for WNV
neuroinvasive disease, due to their susceptibility to infection with the
WNV NY99 strain following inoculation via various routes (64, 65). All
of the mice were housed in HEPA-filtered enclosures within the ABSL-3
facilities at UTMB and were provided with an unlimited supply of food
and water. All animal studies were conducted in accordance with proto-
cols approved by the UTMB IACUC.
The virulence of the viable chimeric viruses compared to that ofWNV
NY99 was determined following infection via the intraperitoneal (i.p.) or
i.c. route of groups of 5 or 10micewith 10 PFU (i.c.) and 100PFU (i.p. and
i.c.). The inocula were tested by back-titration to confirm the virus dose.
Mice were checked daily for 21 days postinfection for signs of infection,
with the checks increasing to twice daily once clinical signs started to
develop.
Assessment of virus distributions in infected mice. Prior to infec-
tion, groups of five mice were anesthetized and subcutaneous IPTT-300
transponder microchips (BMDS, Seaford, DE) were injected to allow
identification and temperature measurements. Temperature and weight
datawere recorded daily throughout the course of the experiment. On day
0, 5 mice that received microchips and an additional 15 mice that did not
receive microchips were inoculated i.p. with 100 PFU of WNV NY99 or
viable chimeric viruses. The virus titer in the inoculum was confirmed by
back-titration.On days 1, 3, 5, 7, and 9 postinfection, groups of threemice
that hadnot receivedmicrochipswere selected at random fromamong the
mice that had been inoculated with each virus and euthanized to collect
blood via cardiac puncture and tissue samples. Blood samples were dis-
pensed into EDTA-containing tubes (Sarstedt, Nümbrecht, Germany).
Hematological analysis of the whole blood was carried out using a He-
mavet 950 instrument (Drew Scientific, Miami Lakes, FL). Liver, spleen,
kidney, lung, and brain tissue samples were removed and deposited in
preweighed 2-ml homogenization tubes containing LysingMatrix D (MP
Biomedicals, Santa Ana, CA).
The anticoagulated blood samples were centrifuged at room temper-
ature for 5 min at 10,000 g to recover plasma, which was removed and
stored at 80°C until needed. The organ tissue-containing tubes were
weighed before and after addition of the tissue to determine tissue
weights. Organ tissue weights were converted to volume equivalents
(1 mg 1 l), and MEM containing 2% FCS and 2 penicillin-strepto-
mycin was added to each homogenization tube to reach a total volume of
500 l. Samples were homogenized using a Qiagen TissueLyser II tissue
disrupter (Qiagen, Germantown,MD) set to full speed for two 90-s cycles.
The samples were spun down, and a further 500 l of medium was
added to each tube to achieve a total volume of 1 ml. The brain tissue
samples were frozen at 80°C until needed, while the other organ
tissue samples were further homogenized for two 120-s cycles at full
speed. The samples were centrifuged again and stored at 80°C until
needed. Virus titers in the plasma and organ tissue samples were deter-
mined by plaque assay starting at a 101 dilution, with titers being re-
ported per milliliter of plasma and per 100 mg of tissue.
Statistical analyses. Statistical analysis of growth kinetics, plaque
sizes, organ titer, and hematology data were performed by analysis of
variance (ANOVA)with Bonferroni post hoc analysis using the Stata (v14)
program (StataCorp, College Station, TX). Survival curve analysis was
performed using a log-rank (Mantel-Cox) test with GraphPad Prism
(v6.0g) software (GraphPad, La Jolla, CA). Comparison of average sur-
vival times was performed using a two-tailed Student’s t test with Mi-
crosoft Excel software (Microsoft, Redmond, WA).
RESULTS
Viability of chimeric viruses. Of the 30 EIII chimeras generated
using the WNV infectious clone plasmids, 16 resulted in recover-
able viruses: all four versions of the four donor viruses most sim-
ilar to WNV (Koutango virus [KOUV], JEV, SLEV, and BAGV).
Deep sequencing of the viable viruses recovered at passage 0 (P0)
revealed only one nonsynonymous mutation present at a fre-
quency of over 20%: an N222Y substitution present at a 80%
frequency in each of the SLEVC/D andBAGVB/C chimeras. Cells
transfected with the nonviable chimeric constructs failed to re-
lease infectious particles into the supernatant following electropo-
ration (as determined by reverse transcription-PCR). Immuno-
staining of the electroporated cell monolayers revealed staining of
individual cells when an anti-WNVMIAF was used but not when
the anti-flavivirus EII MAb 4G2 was used (data not shown), sug-
gesting that E-protein folding was impaired.
Antigenicity of chimeric viruses.Western blotting assays per-
formed using whole-cell lysates prepared from Vero cells infected
with the A or B forms of the chimeras, as well as WNV NY99,
showed similar reactivities with the anti-flavivirus EII 4G2 MAb
(Fig. 2A). The anti-WNV EIII MAb 3A3 had slightly reduced re-
activity with the KOUV chimeras and was not reactive with any of
the other chimeras. The anti-JEV EIII MAb (ab81193) was reac-
tive with the JEV EIII A/B chimeras only. Specific antibodies
against the EIIIs of the other donor viruses were not available, so
instead,MIAFs raised against the donor viruses were used to com-
pare antigenicity changes associated with EIII substitutions (Fig.
2B). Two anti-WNV MIAFs, one against a lineage I WNV strain
and another against a lineage IIWNV strain, showed strong bind-
ing with all the chimeras, most likely due to antibodies targeting
epitopes in domains I and II of the E protein that were retained in
the chimeras. The JEV MIAF also showed significant cross-reac-
tivity, with the band intensities for the JEV chimeras being similar
to those for the other viruses, consistent with the closer antigenic
relatedness of WNV and JEV. The SLEV and BAGV MIAFs
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FIG 2 Antigenicity of chimeric viruses. (A) Reactivity of chimeric E proteins
with monoclonal antibodies against flavivirus EII (MAb 4G2), WNV EIII
(MAb 3A3), and JEVEIII (MAb ab81193); (B) reactivity of chimeric E proteins
with various MIAFs.
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showed much less cross-reactivity. The BAGVMIAF reacted only
with the BAGV chimeras, in agreement with its grouping in the
Ntaya rather than the JE serocomplex.
Due to the higher recovery titers, the greater apparent toler-
ance of the B-form EIII substitutions, and the lack of distinct
antigenic differences between the A and B forms, the B formswere
utilized for further comparative characterization and are hence-
forth referred to as WNV/JEV-EIII, WNV/KOUV-EIII, WNV/
SLEV-EIII, and WNV/BAGV-EIII.
Plaque morphology of recovered chimeric viruses. Distinct
and statistically significant differences in plaque sizes were ob-
served between WNV NY99 and some of the chimeras (Fig. 3A
and B). Ten representative plaques were measured for each virus,
and the sizes were compared by one-way ANOVA with the Bon-
ferroni correction. ForWNVNY99, the plaques in Vero cells after
72 h were large and distinct (3.60  0.52 mm). WNV/JEV-EIII
had a mean plaque size 0.45 mm smaller than that of WNVNY99
(3.15  0.47 mm), although this difference was not statistically
significant (P  0.05). In contrast, WNV/KOUV-EIII had a sig-
nificantly smaller plaque size than WNV NY99 (2.30 0.42 mm;
P	 0.001), with the mean diameter of 1.3 mm forWNV/KOUV-
EIII plaques being smaller than that for NY99 plaques. Similarly,
WNV/BAGV-EIII had a significantly smaller plaque size than
WNV NY99 (1.95 0.37 mm; P	 0.001), with the mean diam-
eter of the plaques being 1.65 mm smaller than that of NY99
plaques. WNV/SLEV-EIII generated large plaques (3.30  0.71
mm) whose sizes were not significantly different from those of
WNV NY99 plaques.
Stability and TS of chimeric viruses.WNVNY99 and all four
chimeras demonstrated high degrees of stability at 4°C, with less
than a 2-fold decrease in titer being noted after 72 h (data not
shown). Some variability between the chimeras was observed
when they were held at 37°C (Fig. 3C).WNVNY99was calculated
to have a half-life of 10.31 h (95% CI, 8.26 to 13.71 h), while
WNV/JEV-EIII had a half-life of 12.13 h (95%CI, 9.58 to 16.53 h).
Both WNV/KOUV-EIII and WNV/SLEV-EIII had half-lives ap-
proximately 2-fold shorter than the half-life of NY99 (5.88 h [95%
CI, 4.74 to 7.75 h] and 5.02 h [95% CI, 4.75 to 5.32 h], respec-
tively). The chimerawith themost divergent EIII sequence,WNV/
BAGV-EIII, had a half-life 4-fold shorter than that of NY99 (2.51
h [95% CI, 2.12 to 3.09 h]).
Previous studies have used temperature sensitivity (TS) assays
(comparison of the virus titer and plaquemorphology at 37°C and
41°C) as a marker of the possible attenuation of the virulence of
WNV strains (60–62). Accordingly, TS assays were runwithWNV
NY99 and the EIII chimeras (Table 2). No significant differences
in the titers of any of the viruses titrated at the two temperatures
were observed; however, the plaque size of WNV/BAGV-EIII was
significantly smaller at 41°C than at 37°C (diameter, 	0.5 mm
versus 2.0 mm).
Growth kinetics of chimeric viruses in Vero and C6/36 cells.
WNVNY99 and the four chimeras were grown in Vero and C6/36
cells following infection at a low MOI of 0.0005 to determine
growth kinetics (Fig. 4). WNV/JEV-EIII grew very similarly to
WNV NY99 in both cell types, with no significant differences in
titer being detected at any of the time points at which titers were
measured. InVero cells, the growth ofWNV/KOUV-EIIIwas sim-
ilar to that of WNV/SLEV-EIII for the first 2 days, with the titers
on these days being within 5-fold of those of WNV NY99. From
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FIG 3 Plaque morphology and particle stability of chimeric viruses. (A) After
72 h of incubation, the plaque morphologies ofWNV/KOUV-EIII andWNV/
BAGV-EIII in Vero cells were significantly smaller than those of WNV NY99,
whereas those of WNV/JEV-EIII and WNV/SLEV-EIII remained similar to
those of the NY99 control. (B) Ten representative plaques were measured for
each chimera, with the mean and standard deviation (Std Dev) plaque sizes
being determined for each. Plaque sizes statistically significantly different from
those of WNV NY99 (P	 0.05, as determined by one-way ANOVA with the
Bonferroni correction) are in bold. (C) Duplicate virus (WNV NY99 and EIII
chimeras) samples were held at 37°C, and aliquots were harvested at 0, 12, 24,
36, 48, and 72 h. Samples were titrated, and the values were normalized to the
titer at 0 h. One-phase decay curves were fitted to the data using GraphPad
Prism (v6.0g) software.
TABLE 2 TS of WNV EIII chimeras
Virus
Titer at:
Log10 difference
in titer P valuea37°C 41°C
WNV NY99 3.73 108 3.85 108 0.013 0.418
WNV/KOUV-EIII 2.27 108 1.78 108 0.104 0.109
WNV/JEV-EIII 3.21 108 2.45 108 0.118 0.146
WNV/SLEV-EIII 3.70 107 1.45 107 0.406 0.135
WNV/BAGV-EIII 3.80 106 2.30 106b 0.218 0.081
a Titers were compared by one-way ANOVA with the Bonferroni correction.
b The average plaque size was significantly smaller (	0.5 mm) at 41°C than at 37°C
(2.0 mm).
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day 3 onward, the titers of WNV/KOUV-EIII declined more rap-
idly than those ofWNVNY99, although the titers ofWNV/SLEV-
EIII remained similar to those of WNV NY99 from days 3 to 5,
with no significant differences being noted on either day 3 or 4.
Within C6/36 cells, WNV/KOUV-EIII grew similarly to WNV
NY99, although the titers of WNV/KOUV-EIII were significantly
lower than those of NY99 on days 3 and 5. In contrast, in C6/36
cells, WNV/SLEV-EIII grew with titers significantly higher than
those of WNV NY99 on days 2 and 3, but the titers on days 4 and
5 were within 2-fold of those of NY99.
WNV/BAGV-EIII displayed the most significant difference in
growth from that of WNV NY99 in both cell types. Within Vero
cells, the initial growth of WNV/BAGV-EIII was slower than that
of NY99, and WNV/BAGV-EIII had a statistically significant 33-
fold lower titer than NY99 on day 1. However, by day 2 theWNV/
BAGV-EIII titer had increased so that it was only 5-fold lower than
that ofWNVNY99. Similar to the findings forWNV/KOUV-EIII,
the titers ofWNV/BAGV-EIII declinedmore rapidly than those of
WNV NY99 on days 3 to 5. In C6/36 cells, the growth of WNV/
BAGV-EIII was retarded, with titers significantly lower than those
of NY99 being detected on day 3 and day 5 (12-fold and 51-fold
lower, respectively).
Sequence stability of chimeric viruses. All four of the chime-
ric viruses, as well as WNVNY99, were passaged 10 times in Vero
cells, and the E-coding region was sequenced to determine se-
quence stability in and around the EIII region. At P10, WNV
NY99 had a single amino acid substitution in E, E390G, a previ-
ously described tissue culture adaptation that affects glycosami-
noglycan binding (15, 16). No mutations were detected in either
theWNV/JEV-EIII orWNV/KOUV-EIII E sequence at P10. Both
the WNV/SLEV-EIII and WNV/BAGV-EIII P10 chimeras en-
coded a consensus N222Y substitution, with WNV/BAGV-EIII
also possessing a conservative L311I mutation at P10.
Neutralization of chimeric viruses.Neutralization of the chi-
meric viruses with anti-WNV MIAFs, a rabbit serum raised
against WNV EIII (63), and two serum samples obtained from
WNV-infected humans (63) demonstrated antigenic differences
among the different chimeras, particularly with WNV/JEV-EIII
(Table 3). As expected, rabbit anti-WNV EIII polyclonal serum
showed the greatest WNV-specific activity, with strong neutral-
ization of WNV NY99 and WNV/KOUV-EIII but a significantly
weaker neutralization of all of the other chimeras. Significant dif-
ferences in neutralizing activity against the EIII chimera viruses
were also observed for both of the anti-WNV MIAFs. The anti-
WNV lineage I MIAF neutralized the WNV/KOUV-EIII and
WNV/BAGV-EIII chimeras to levels similar to those at which it
neutralized WNV NY99 (NT50s, 2,560 to 5,120), but WNV/JEV-
EIII and WNV/SLEV-EIII were significantly less well neutralized
(NT50s, 640). Similar results were also seen with the anti-WNV
lineage II MIAF, although theWNV/BAGV-EIII chimera was less
readily neutralized by the lineage II MIAF than by the lineage I
MIAF. Consistent with previous reports that relatively little of the
neutralizing antibody response in humans targets epitopes in EIII,
both human serum samples neutralized all chimeras to levels
comparable to those at which they neutralized the NY99 parent,
with the exception of an 8-fold lower neutralization titer for
WNV/JEV-EIII with the 026 human serum sample than the 022
human serum sample. A 4-fold change in neutralization titer
compared to that of WNV NY99 was deemed significant.
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FIG 4 In vitro growth kinetics for chimeric viruses. Growth kinetics were
determined forWNVNY99 and each of the four chimeras following infection
of Vero (A) and C6/36 (B) cells in triplicate flasks at a low MOI of 0.0005.
Statistical significance was determined by ANOVA with the Bonferroni cor-
rection for all viruses by comparison to the results forWNVNY99 (*,P	 0.05;
**, P 	 0.01; ***, P 	 0.001; the different colors correspond to individual
chimeras). The graphs show mean values with standard errors.
TABLE 3 Neutralization of WNV EIII chimeras by polyclonal antisera
Virus
PRNT50
a
Anti-WNV EIII
rabbit pAbb
Lineage I MIAF
(T-35570)
Lineage II MIAF
(T-35345)
Anti-WNV human
serum 022
Anti-WNV human
serum 026
WNV NY99 1,280 5,120 1,280 1,280 10,240
WNV/KOUV-EIII 2,560 2,560 2,560 1,280 10,240
WNV/JEV-EIII 80 640 80 1,280 1,280
WNV/SLEV-EIII 	40 640 80 1,280 5,120
WNV/BAGV-EIII 	40 2,560 640 1,280 5,120
a PRNT50, 50% plaque reduction neutralization titer.
b pAb, polyclonal antibody.
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Mouse virulence studies. In order to determine the effects of
chimerization on virulence following peripheral infection, groups
of 10 or 14 3- to 4-week-old female Swiss Webster mice were
inoculated via the i.p. route with 100 PFU of WNV NY99 or a
chimeric virus (Fig. 5A). WNV/JEV-EIII maintained high viru-
lence, with no significant differences in survival between mice
infected with WNV/JEV-EIII and mice infected with WNVNY99
being detected. WNV/KOUV-EIII caused significantly lower
mortality (25%) than the NY99 parent virus or the JEV chimera,
and mice infected with WNV/KOUV-EIII displayed protracted
survival times compared with the average survival times of mice
infected with WNV NY99 and the other chimeras. Surprisingly,
the virulence of WNV/SLEV-EIII was completely attenuated fol-
lowing i.p. inoculation, despite efficient growth in vitro. Interest-
ingly, even though WNV/BAGV-EIII had the most distinct EIII
sequence of the donor viruses, it caused 14% mortality. Viruses
isolated from mouse brains following lethal KOUV and BAGV
chimera infections had no additional mutations in E, suggesting
that further adaptation of the chimeric E sequence was not re-
quired for neuroinvasion leading to lethal disease in those ani-
mals.
Owing to the significant differences in neuroinvasive disease
following i.p. inoculation, the neurovirulence of the chimeras was
assessed by direct intracranial inoculation (Fig. 5B). Groups of 5
or 10 mice were infected with 10 or 100 PFU of WNV NY99 or a
chimeric virus via the i.c. route. As expected, WNV NY99 (which
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FIG 5 Virulence of chimeric viruses following i.p. and i.c. inoculation. (A) Three- to 4 week-old female SwissWebster mice were infected with 100 PFU of virus
i.p. (n
 10 or 14). (B) Swiss Webster mice were infected with WNV NY99 (n
 5 per group) or an EIII chimera (n
 5 per group for WNV/JEV-EIII, n
 10
per group forWNV/KOUV-EIII,WNV/SLEV-EIII, andWNV/BAGV-EIII) at 100 or 10 PFU via the i.c. route. For themice that succumbed to infection, average
survival times (ASTs) with standard deviations were calculated and are shown on the right. Comparison of the mortality curves for mice infected with the
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has a 50% lethal dose of	1 PFU when given i.c.) was universally
lethal at both challenge doses. Similar to the results obtained
with the i.p. inoculations, WNV/JEV-EIII caused high rates of
mortality at both doses, although one of the five animals sur-
vived following infection with the 10-PFU dose. At the 10-PFU
dose, WNV/SLEV-EIII, WNV/KOUV-EIII, and WNV/BAGV-
EIII all appeared to have lower neurovirulence than WNV NY99,
with the mortality rates for mice infected with these three chime-
ras being reduced compared to those for mice infected withWNV
NY99. At the 100-PFU dose, the mortality rates for mice infected
with WNV/KOUV-EIII and WNV/BAGV-EIII were 60% and
80%, respectively.
Assessment of virus distributions in infected mice. Periph-
eral inoculation with 100 PFU of each virus had revealed that the
virulence of some of the EIII chimeras was significantly attenuated
compared to that of WNV NY99, despite similar in vitro growth,
plaquing, temperature sensitivity, and particle stability pheno-
types. In order to better characterize the course of infection, a
serial sacrifice studywas carried outwithmice infectedwith one of
the four chimeras andWNVNY99.Cohorts of 20micewere dosed
with 100 PFU of each virus via the i.p. route, with the inoculating
doses being confirmed by back-titration. Microchips were placed
in 5 mice in each cohort to allow daily temperature and weight
measurements, and for each virus, an additional 15 mice that did
not receive microchips were used for biosampling on days 1, 3, 5,
7, and 9.
The temperatures of all of the mice remained similar for the
first 7 days of the infection. For the WNV NY99- and WNV/JEV-
EIII-infected mice, rapid declines in body temperature (approxi-
mately 3°C per day) were observed from day 8 until death (Fig.
6A). Similarly, the lethal KOUVB-form infections also resulted in
body temperature reductions, although these were less rapid, with
the rate of temperature loss rarely exceeding 1°C per day. Temper-
ature changes were not observed during nonlethal infections or in
mice that died prior to day 9. Weight loss was observed with all of
the infectedmice starting on day 7. Three weight loss profiles were
identified (Fig. 6B): a rapid loss of up to 3 g between day 7 and the
time of death or euthanasia following infection with WNV NY99
and WNV/JEV-EIII, an approximately 2-g weight loss between
days 7 and 14 following infection with WNV/KOUV-EIII and
WNV/SLEV-EIII, and a small, 2-day decrease following infection
with WNV/BAGV-EIII.
All of the viruses generated detectable viremia that peaked on
day 3 postinfection (Fig. 7A). ForWNVNY99 andWNV/KOUV-
EIII, viremia was mostly detectable only on days 1 and 3, with the
mean peak titers for both viruses being very similar at approxi-
mately 105 PFU/ml. WNV/JEV-EIII also generated a robust
viremia, although the peak viremia of WNV/JEV-EIII was almost
7-fold lower than that ofWNVNY99.Moreover, the durationwas
protracted compared to that for NY99, with the majority of the
mice still having detectable viremia on day 5. Both WNV/SLEV-
EIII and WNV/BAGV-EIII generated viremias in only a subset of
animals at each time point during days 3 to 7, and the peak
viremias were considerably lower than those of the other viruses.
As expected, neuroinvasion was consistently seen with
WNV NY99 (Fig. 7B) beginning on day 5. Curiously, despite
causing 100% mortality, neuroinvasion with WNV/JEV-EIII
was less consistent, with at least one virus-negative brain sam-
ple being detected at each of the later time points. In spite of the
lack of mortality associated with theWNV/SLEV-EIII chimera,
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FIG 6 Temperature and weight changes following i.p. inoculation with EIII
chimeras. Groups of five 3- to 4-week-old female Swiss Webster mice were
infected with 100 PFU of WNV NY99 or an EIII chimera via the i.p. route.
Temperatures (A) and weights (B) were measured daily for 21 days following
infection. Three different weight profiles emerged: one for the WNV NY99-
and WNV/JEV-EIII-infected mice (Bi), a second one for the WNV/KOUV-
EIII- and WNV/SLEV-EIII-infected mice (Bii), and a third for the WNV/
BAGV-EIII-infected mice (Biii).
Flavivirus Receptor-Binding Domain Chimeras
May 2016 Volume 90 Number 9 jvi.asm.org 4765Journal of Virology
occasional neuroinvasion was detected on days 5 and 7 (i.e.,
after the detection of viremia) but was not associated with any
clinical signs of infection. Despite the occasional mortality ob-
served during the initial comparisons with WNV/KOUV-EIII-
and WNV/BAGV-EIII-infected mice, only one WNV/KOUV-
EIII-infected mouse had detectable neuroinvasion in this ex-
periment.
Titers in the peripheral organs were also variable between the
viruses (Fig. 7C to F). WNVNY99 consistently grew to high titers
in all of the organs studied, except the liver. WNV/JEV-EIII had a
distribution similar to that of WNV NY99, but the titers were
generally lower than those of NY99, and in contrast to NY99, the
virus appeared to be more readily cleared from the lung. Despite
the strong, WNV NY99-like viremia generated by the WNV/
KOUV-EIII chimera, it was rarely detected in peripheral organs
with the exception of the kidney, in which it grew similarly to the
parental virus, suggesting a potential shift in tissue tropism for
that chimera.WNV/SLEV-EIII andWNV/BAGV-EIII were infre-
quently detected in peripheral organs, with even the kidney only
occasionally having detectable titers.
Hematological analysis at each time point revealed few differ-
ences of note (data not shown). There were no significant differ-
ences in the total white blood cell count between the infected and
mock-infected mice, although the data suggested a trend toward
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FIG 7 Organ titers following i.p. inoculation. Three- to 4-week-old female SwissWebstermice were inoculated with eitherWNVNY99 or an EIII chimera at 100
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leukocytopenia in all infected mice, particularly early in the infec-
tion, mostly resulting from apparent lymphocytopenia. Altera-
tions to red blood cell counts and their associated metrics were
minimal.
DISCUSSION
The envelope glycoprotein is the main protein component
present on the surface of mature flavivirus virions and is re-
sponsible for a range of processes during viral attachment and
entry. Previous studies have suggested that EIII contributes
significantly to the binding of flaviviruses to cell surface recep-
tors (6, 10, 12, 28, 66, 67), although other regions of the E
protein also contribute to interactions with cell surface ligands.
A previous study by Bielefeldt-Ohmann et al. showed that trun-
cated, secretable chimeric E proteins incorporating the EIII do-
main fromDENV-3 and the EI-EII domains fromDENV-2 could
be expressed frommammalian cells andmaintained the antigenic
properties of both protein regions (68), while a recent paper by
Gallichotte et al. has demonstrated that viruses with interserotype
substitutions of EIII (DENV-4 with DENV-2 EIII) are viable and
that such substitutions lead to the generation of chimeras with
shared antigenic properties (69).
We aimed to test the tolerance of WNV for substituted EIII
sequences and the effects that such substitutions may have on the
growth, virulence, and antigenicity of the chimeric viruses. Our
data clearly show that EIII substitution is feasible for the genera-
tion of infectious chimeric WNVs but that there are substantial
constraints on the sequence identity of the substituted domain:
recoverable viruses had amino acid identities greater than 65% in
both EIII and E as a whole compared to the sequence of WNV
NY99, while more divergent EIII sequences were not tolerated.
Analysis of the sequences that were tolerated and not tolerated did
not reveal any obvious shared motifs or structural features that
allowed chimera viability (Fig. 1B), but it seems likely that the
constraints on EIII substitution are imposed by intra- and inter-
molecular interactions between EIII and the rest of E as well as,
potentially, between EIII and prM/M.
As expected, substitution of alternative EIII sequences led to
antigenic changes in the chimeric proteins that were detectable by
Western blotting using virus-specific MAbs or polyclonal MIAFs.
Previous studies by others have demonstrated that depletion of
anti-EIII antibodies from human serum has a minimal effect on
virus neutralization, whereas neutralizing anti-EIII responses are
more prominent in mouse serum (70, 71). The Western blotting
and neutralization data obtained with our EIII chimeras are
mostly in agreement with these observations, showing that these
viruses may also be a useful tool to complement antibody deple-
tionmethods for discerning the role of EIII in immune responses.
One interesting observation from the neutralization data was the
relatively strong neutralization of the WNV/BAGV-EIII chimera
(which showed NT50s similar to those of WNV NY99 and WNV/
KOUV-EIII with the anti-WNV MIAFs and NT50s significantly
higher than those of WNV/JEV-EIII and WNV/SLEV-EIII), de-
spite having little antigenic cross-reactivity at the EIII level, as
evidenced by the relative specificity of the anti-WNV EIII poly-
clonal antibody and the anti-BAGVMIAF. This may suggest that
attachment to Vero cells and/or entry into Vero cells is less EIII
dependent for the WNV/BAGV-EIII chimera than for the other
viruses, with antibody recognition of other regions of E playing a
more significant role in the neutralization of this virus than the
neutralization of the others. Further studies would be necessary to
confirm whether this is the case.
The in vitro growth, plaquing, and TS data suggest that substi-
tution of EIII did not have a strong adverse effect on the chimeric
viruses. The peak titers of all chimeras in Vero cells were within
10-fold of the titer of the parental wild-typeNY99 virus, which is a
difference comparable to that previously reported for nonglyco-
sylated variants of WNV NY99 (72). In addition, stability assays
run with WNV NY99 gave results similar to those observed by
Dowd et al. (2014), using reporter virus particles (73). Only the
BAGV chimera had a 2-fold reduction in apparent half-life at
37°C, and the BAGV chimerawas also the only virus to display any
difference from wild-type virus NY99 in the TS comparison, hav-
ing a reduced plaque size at 41°C compared to that at 37°C.
While the effects of chimerization were associated with some
significant differences with respect to in vitro growth and plaquing
phenotypes, they were evenmore pronounced in vivo, with differ-
ences in virulence between the EIII chimeras and WNV NY99
being observed after administration by the i.p. and/or i.c. route.
Previous studies with engineered or selectedmutants ofWNVand
some other JEV complex flaviviruses have identified single amino
acid mutations that can attenuate mouse neuroinvasiveness (13,
15, 16, 74, 75) by multiple mechanisms that may be associated
with direct or indirect effects on receptor binding or with in-
creased glycosaminoglycan binding due to charge changes. Al-
though it is possible that the reductions in the virulence of the EIII
chimeras may have occurred due to negative effects on virion as-
sembly, structure, or stability, the lack of obvious effects on in vitro
behavior suggests that specific characteristics of the particular EIII
sequence used likely play a more significant role in determining
viral pathogenesis in mice. The range of infection outcomes and
the changes in virus distribution in peripheral tissues following
i.p. inoculation suggest that the introduction of alternative EIII
sequences may have resulted in altered tissue tropisms for these
viruses.
A very surprising observationwas the strong attenuation of the
virulence of the WNV/KOUV-EIII chimera. A recent study com-
paring the virulence of KOUV strain DaK Ar D 5443 and WNV
NY99 in Swiss mice reported that KOUV was more virulent fol-
lowing peripheral inoculation than WNV NY99 and that the en-
hanced virulence appeared to be due to delayed innate and adap-
tive immune responses (76). Those authors hypothesized that this
could be associated, at least in part, with a cluster of amino acid
differences located within EIII (76). The chimeric WNV/KOUV-
EIII showed a significant attenuation in virulence compared to the
virulence of WNV NY99, with much lower mortality rates being
detected following peripheral and intracranial inoculation, al-
though some weight loss was observed for infected animals. In
addition, the WNV/KOUV-EIII chimera showed significant dif-
ferences in organ distribution from that of WNVNY99. This chi-
mera produced a strong WNV NY99-like viremia and grew to
titers equivalent to those of NY99 in the kidney, but there was
minimal evidence for infection/replication in the other organs
studied. Comparison of the KOUV EIII sequence with that of
WNV NY99 (Fig. 1) revealed that the majority of the 11-amino-
acid differences occur in regions of the protein that would be
buried within the virion structure. However, a string of variable
amino acids on the DE loop and a glutamic acid-to-aspartic acid
substitution at residue 390 in a putative RGD/E integrin-binding
motif would be surface accessible. None of these residues are in
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immediate proximity to previously identified attenuating muta-
tions in the BC loop (13), nor do they result in net charge changes
typical of potentially attenuating glycosaminoglycan-binding ad-
aptations. Nevertheless, our findings suggest that the reported in-
creased virulence of wild-type KOUV in mouse models is not due
to the amino acid differences that occur in EIII.
WNV/JEV-EIII behaved very similarly to WNV NY99 within
the mouse model, showing virulence similar to that of NY99 fol-
lowing infection by both routes of administration. BothNY99 and
WNV/JEV-EIII infection resulted in substantial temperature
drops from day 8 until death, although, unlikeWNV infections in
humans and nonhuman primates, the infected mice showed no
febrile phase (77, 78). In addition, mice infected with both viruses
showed significant weight loss from day 7 onward. Subtle differ-
ences in organ distribution still occurred betweenWNV/JEV-EIII
and NY99, not the least of which was a reduced frequency of neu-
roinvasion, despite similar overall mortality rates, with the titers
of WNV/JEV-EIII in the other organs generally being lower than
those ofWNVNY99 in infectedmice. In addition,WNV/JEV-EIII
caused a protracted viremia, possibly suggesting less efficient
clearance from the periphery by the immune system.
The virulence of WNV/SLEV-EIII was highly attenuated in
vivo, even though it had in vitro growth, plaquing, stability, andTS
phenotypes similar to those of WNV NY99. Even following i.c.
inoculation, the virulence of WNV/SLEV-EIII appeared to be at-
tenuated, with WNV/SLEV-EIII causing a significantly lower
mortality rate than NY99 following a 10-PFU dose. After periph-
eral inoculation, the WNV/SLEV-EIII viremia was detectable but
significantly lower than that of WNVNY99. In spite of the appar-
ently rapid clearance of WNV/SLEV-EIII from the infected mice,
the weight loss following infection in WNV/SLEV-EIII-infected
mice was similar to that inWNV/KOUV-EIII-infected mice, rais-
ing the possibility that the virus may have infected and remained
in an organ that was not examined.
In summary, these studies have demonstrated that viable flavi-
virus EIII chimeras that are structurally stable and replicate effi-
ciently in mammalian and mosquito cell lines can be produced.
These chimeras behaved significantly differently from one an-
other and from the WNV NY99 backbone virus in vivo, with chi-
merization having substantial effects on virulence and the organ
distribution. Although we have identified the differences in virus
distribution at the organ level, more detailed studies are needed to
determine whether specific cell types are differentially infected by
wild-type WNV NY99 versus the EIII chimeras. Coupled with
WNV mutants with other single- and multisite mutations, these
chimeras may be used to more extensively define the contribu-
tions of EIII to the tropism and pathogenesis of WNV. This pro-
tein domain chimerization strategy is also applicable to investiga-
tions with other medically important flaviviruses.
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